RESEARCH PEPTIDE FUNDAMENTALS
Five Research Peptides. One Straight Answer.
A practical rundown of what US research communities are actually studying right now — tissue repair, gut inflammation, cellular energy, and two metabolic receptor agonists — with the evidence sorted from the noise.
BPC-157
A stable gastric pentadecapeptide studied in animals for tissue and gut repair. One tiny human safety pilot exists. Everything else is rodent data.
Read the research →
KPV
A three-amino-acid fragment of alpha-MSH studied for gut inflammation. No published human trials exist at all — this one is entirely preclinical.
Read the research →
NAD+
The cell's core redox coenzyme, sold as a supplement and an IV therapy. Human trials confirm it raises blood NAD+ reliably; they don't yet confirm it does much else.
Read the research →
Retatrutide
An investigational triple-receptor agonist with the largest weight-loss numbers of any incretin compound tested — still in Phase 3, still unapproved, still gray-market only.
Read the research →
Tirzepatide
The lead compound on this desk — an FDA-approved dual incretin agonist with the deepest trial record of the five, including a head-to-head win over semaglutide.
Read the research →The short version
Research Peptides US covers five peptides that show up constantly in research forums, supplement shelves, and clinical literature, and treats them the same blunt way: what does the published evidence actually say, and where does it stop? A peptide is just a short chain of amino acids — the building blocks of protein — small enough to be made in a lab and, in some cases, potent enough to change how the body signals itself.
The five here span very different territory. BPC-157 is a gut-derived peptide studied mostly in rats for tissue repair. KPV is a tiny anti-inflammatory fragment that has never been tested in a single published human trial. NAD+ is a coenzyme every cell already runs on, marketed as a supplement and an IV drip. Retatrutide and tirzepatide are metabolic receptor agonists — tirzepatide is FDA-approved, retatrutide is not, and both come from the same incretin-pharmacology family that has reshaped obesity and diabetes research over the past several years.
This site does not sell anything, does not tell anyone what dose to take, and does not pretend animal data or a forum thread is the same thing as a clinical trial. It reports what was studied, in whom, and how far that evidence honestly reaches.
The US research-peptide landscape at a glance
Walk into any US research-peptide discussion and these five names come up constantly, for different reasons. BPC-157 gets requested for tendons, joints, and gut issues. KPV shows up in gut-health and inflammation threads despite having zero human trial data behind it. NAD+ gets sold in IV bars and supplement aisles on a longevity pitch. Retatrutide and tirzepatide dominate the weight-loss and metabolic conversation, with retatrutide treated as the "next" tirzepatide even though it hasn't cleared Phase 3.
What ties them together isn't a shared mechanism — it's a shared gap between hype and evidence maturity. Two of the five (tirzepatide, and to a lesser extent NAD+'s precursor forms) have real human trial programs behind them. Two (BPC-157, retatrutide) have thin-to-moderate human data and heavy animal or early-phase backing. One (KPV) has no human data whatsoever. Reading them side by side, rather than one at a time on a vendor's product page, is the only way to see that gap clearly. This site's comparison page puts the five head to head on exactly that basis.
What are research peptides, and what this site won't do
"Research peptide" is the label suppliers use for a peptide sold for laboratory use, not human consumption — meaning it hasn't gone through FDA approval, isn't manufactured under pharmaceutical quality control, and carries no verified purity or dosing standard outside a formal study. Some of the compounds on this desk (tirzepatide) have graduated to approved-medicine status through full clinical trial programs. Most have not, and some (KPV) have barely entered human study at all.
This site describes what the literature says a peptide does in animals, in cells, or in the small number of humans who have been formally studied — and separately, what people in research-use communities report anecdotally, clearly labeled as such. It never recommends a dose, a use, or a source. It does not sell peptides, does not link to vendors, and does not pretend a Reddit thread is a clinical trial. Every specific number on this site — a percentage, a half-life, a trial size — traces back to a numbered citation.